Aurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with multiple myeloma. All patients achieved clinical response, with no high-grade safety events reported. The Indian drug regulator has approved the commencement of a phase-2 trial.
